Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind trial evaluating idelalisib plus rituximab vs control in previously treated chronic lymphocytic leukemia has completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Idelalisib (idelalisib)
• Rituximab (rituximab)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2014-10-16